Logo

American Heart Association

  2
  0


Final ID: MDP942

Automated IVUS Image Analysis for Cardiac Allograft Vasculopathy Surveillance in Heart Transplant Recipients

Abstract Body (Do not enter title and authors here): Background: Cardiac allograft vasculopathy (CAV) is a heterogenous and poorly understood process of immune and non-immune factors occurring within the coronary artery and a leading cause of graft failure in heart transplant recipients. Intravascular ultrasound (IVUS) is used as an adjunct to angiography to significantly increase the sensitivity for detection disease, however by current standards < 1% of IVUS images are graded for maximal intimal thickness (MIT) or scored for severity of CAV. The majority of IVUS frames remain unanalyzed.
Aims: Demonstrate the application of pre-trained DeepIVUS machine learning model to annotate IVUS images obtained from transplant patients, establishing the accuracy of this tool in a new patient population.
Methods: We reviewed 963 clinically annotated IVUS frames from heart transplant recipients, 706 were selected after screening for completeness. DeepIVUS was used to segment the frames and create predictions of the vessel lumen, plaque area and intimal thickness (IT) measurements around the entire vessel lumen. To compare with expert annotations, typically a single caliper measurement, the 90th percentile value of DeepIVUS-predicted IT was used. A confusion matrix was used to assess the model's ability to accurately classify predicted and true IT values, utilizing a threshold of 0.5 mm.
Results: In 163/706 frames (23.1%), DeepIVUS labeling resulted in segments with jagged or non-physiologic shapes. These were automatically discarded using a quantitative ovalness criteria, Figure 1. Agreement between DeepIVUS predicted MIT and expert measured MIT in the remaining 543 frames yielded a strong Pearson correlation coefficient of 0.81 with an R2 of 0.65, Figure 2A. The linear fit was used to determine the DeepIVUS IT cutoff (0.554mm) which corresponded to clinical cutoff of 0.5mm. Using this value, DeepIVUS correctly classified 86.6% of frames (sensitivity 85.1%, specificity 87.9%, aF1 0.86), Figure 2B.
Conclusion: We present a first use applcation of a pre-trained Deep IVUS image analysis in a transplant population demonstrating good agreement with expert clinical annotation. In current practice, a small fraction of images from each IVUS study are annotated. With an ovalness criteria providing quality control, DeepIVUS may be applied to non-annotated frames, allowing significantly more frames per IVUS study to be analyzed. Future studies are warranted to understand the prognostic capabilities of these automated annotations.
  • Birs, Antoinette  ( SULPIZIO CARDIOVASCULAR CENTER , La Jolla , California , United States )
  • Lyu, Wenzhou  ( University of California San Diego , La Jolla , California , United States )
  • Ang, Lawrence  ( SULPIZIO CARDIOVASCULAR CENTER , La Jolla , California , United States )
  • Adler, Eric  ( SULPIZIO CARDIOVASCULAR CENTER , La Jolla , California , United States )
  • Mahmud, Ehtisham  ( SULPIZIO CARDIOVASCULAR CENTER , La Jolla , California , United States )
  • Contijoch, Francisco  ( University of California San Diego , La Jolla , California , United States )
  • Author Disclosures:
    Antoinette Birs: DO NOT have relevant financial relationships | Wenzhou Lyu: DO NOT have relevant financial relationships | Lawrence Ang: No Answer | Eric Adler: DO have relevant financial relationships ; Employee:Lexeo Therapeutics:Active (exists now) ; Consultant:Kiniska Pharmaceuticals:Past (completed) ; Consultant:Abbott:Past (completed) ; Consultant:Abiomed:Past (completed) ; Ownership Interest:Papillion Therapeutics:Active (exists now) ; Other (please indicate in the box next to the company name):Solid Biosciences:Past (completed) ; Research Funding (PI or named investigator):Rocket Pharmaceuticals:Past (completed) ; Royalties/Patent Beneficiary:Rocket Pharmaceuticals:Active (exists now) ; Individual Stocks/Stock Options:Lexeo Therapeutics:Active (exists now) ; Royalties/Patent Beneficiary:Lexeo Therapeutics:Active (exists now) | Ehtisham Mahmud: No Answer | Francisco Contijoch: DO have relevant financial relationships ; Research Funding (PI or named investigator):Siemens Healthineers:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Updates in Heart Transplant

Sunday, 11/17/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
A large-scale multi-view deep learning-based assessment of left ventricular ejection fraction in echocardiography

Jing Linyuan, Metser Gil, Mawson Thomas, Tat Emily, Jiang Nona, Duffy Eamon, Hahn Rebecca, Homma Shunichi, Haggerty Christopher, Poterucha Timothy, Elias Pierre, Long Aaron, Vanmaanen David, Rocha Daniel, Hartzel Dustin, Kelsey Christopher, Ruhl Jeffrey, Beecy Ashley, Elnabawi Youssef

Beyond Static Cold storage: Partial freezing for extending heart preservation and improving recovery

Singh Gurjit, Al-attar Rasha, Lopera Higuita Manuela, Chen Maya, Pugeda Tyler, Uygun Korkut, Toner Mehmet, Tessier Shannon

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available